Frequent Antibiotic Use and Second Breast Cancer Events
Menée à partir de données médicales portant sur 4 216 patientes atteintes d'un cancer du sein de stade I/II diagnostiqué entre 1990 et 2008 (âge : 18 ans et plus ; durée médiane de suivi : 6,7 ans), cette étude évalue l'association entre l'utilisation régulière d'antibiotiques et le risque de développer un second cancer du sein
Background : Antibiotic use may be associated with higher breast cancer risk and breast cancer mortality, but no study has evaluated the relation between antibiotic use and second breast cancer events (SBCE). Methods : We conducted a retrospective cohort study among women ≥18 years, diagnosed with incident stage I/II breast cancer during 1990-2008. Antibiotic use and covariates were obtained from health plan administrative databases and medical record review. Frequent antibiotic use was defined as ≥4 antibiotic dispensings in any moving 12-month period after diagnosis. Our outcome was SBCE defined as recurrence or second primary breast cancer. We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) and 95% confidence intervals (CI), accounting for competing risks. Results : 4,216 women were followed for a median of 6.7 years. Forty percent were frequent antibiotic users and 558 (13%) had a SBCE. Results are suggestive of a modest increased risk of SBCE (HR 1.15, 95% CI 0.88-1.50) among frequent antibiotic users compared to nonusers. Any potential increased risk was not supported when we evaluated recent use and past use. We observed no dose-response trends for SBCE with increasing duration of antibiotic use nor did we find evidence for altered SBCE risk in the antibiotic classes studied. Conclusions : Frequent antibiotic use may be associated with modestly elevated risk of SBCEs, but the association was not significant. Impact : Additional investigation by antibiotic class and underlying indication are important next steps given the high prevalence of frequent antibiotic use and growing number of breast cancer survivors.